This study aims to characterize pathway-specific mutations in TP53, WNT, PI3K, TGF-Beta, and RTK/RAS signaling among H/L and NHW patients, assess tumor mutation burden, and evaluate the prognostic implications of these alterations. Here, TP53 is linked to neoplasm.